MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

Boston Scientific Corp.

Gesloten

SectorGezondheidszorg

96.33 0.52

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

94.54

Max

97.2

Belangrijke statistieken

By Trading Economics

Inkomsten

123M

795M

Verkoop

398M

5.1B

K/W

Sectorgemiddelde

58.458

35.739

Winstmarge

15.708

Werknemers

53,000

EBITDA

155M

1.4B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+31.79% upside

Dividenden

By Dow Jones

Volgende Winsten

22 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-8.1B

145B

Vorige openingsprijs

95.81

Vorige sluitingsprijs

96.33

Nieuwssentiment

By Acuity

44%

56%

130 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Boston Scientific Corp. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 jul 2025, 11:16 UTC

Winsten

Boston Sci 2Q Net Surges, Company Boosts '25 EPS View on Cardiology Demand

23 apr 2025, 12:16 UTC

Winsten
Belangrijke Marktbewegers

Boston Scientific Shares Higher on Rosy Outlook, 1Q Beats

3 mrt 2025, 12:35 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

9 sep 2025, 12:58 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Elutia's Bioenvelope Business for $88M

9 sep 2025, 12:31 UTC

Acquisities, Fusies, Overnames

Elutia Announces Sale of BioEnvelope Business to Boston Scientific for $88M

23 jul 2025, 10:32 UTC

Winsten

Boston Scientific Sees 3Q Sales Up 17%-19%, Organic Sales Up 12%-14% >BSX

23 jul 2025, 10:31 UTC

Winsten

Boston Scientific Sees 2025 Sales Up 18%-19%, Organic Sales Up 14%-15% >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific Sees FY EPS $1.89-EPS $1.93 >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific 2Q Organic Sales Up 17.4% >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific 2Q EPS 53c >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific 2Q Sales $5.06B >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific Sees 3Q Adj EPS 70c-Adj EPS 72c >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific 2Q Adj EPS 75c >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific Sees FY Adj EPS $2.95-Adj EPS $2.99 >BSX

23 jul 2025, 10:30 UTC

Winsten

Boston Scientific Sees 3Q EPS 44c-EPS 46c >BSX

23 apr 2025, 10:32 UTC

Winsten

Boston Scientific Sees 2Q Reported Sales Up 17.5%-19.5%, Organic Sales Up 13%-15% >BSX

23 apr 2025, 10:31 UTC

Winsten

Boston Scientific Sees 2025 Reported Sales Up 15%-17%, Organic Sales Up 12%-14% >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific 1Q EPS 45c >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific 1Q Adj EPS 75c >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific Sees FY Adj EPS $2.87-Adj EPS $2.94 >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific 1Q Sales $4.66B >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific Sees 2Q Adj EPS 71c-Adj EPS 73c >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific Sees 2Q EPS 45c-EPS 47c >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific 1Q Organic Sales Up 18.2% >BSX

23 apr 2025, 10:30 UTC

Winsten

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

3 mrt 2025, 11:59 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3 mrt 2025, 11:58 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3 mrt 2025, 11:58 UTC

Acquisities, Fusies, Overnames

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5 feb 2025, 21:33 UTC

Winsten

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 feb 2025, 15:20 UTC

Winsten

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

Peer Vergelijking

Prijswijziging

Boston Scientific Corp. Prognose

Koersdoel

By TipRanks

31.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 126.32 USD  31.79%

Hoogste 140 USD

Laagste 115 USD

Gebaseerd op 23 Wall Street-analisten die 12-maands prijsdoelen bieden voor Boston Scientific Corp. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

23 ratings

23

Buy

0

Hold

0

Sell

Technische score

By Trading Central

102.95 / 104.93Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

130 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat